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Exposure during pregnancy to pharmaceu-
ticals and environmental chemicals
remains a worldwide problem. Assessing
risk for human developmental toxicity is a
major obstacle in drug development, as it
relies on data from animal experiments,
with associated concordance problems. A
common understanding of basal mecha-
nisms of developmental toxicity could
assist risk assessment, but such mecha-
nisms have unfortunately remained elu-
sive. How individual teratogenic agents
induce early developmental errors, and
how widely different teratogens induce
apparently similar defects by common or
distinct mechanisms are still largely
unknown. Compared with most estab-
lished adult organs, the mammalian
embryo comprises a moving target of
highly dynamic cell interactions. This
inherent complexity impedes the mecha-
nistic interpretation of a chemical insult
and may ultimately preclude what appear
as more desirable in vitro methods from
completely replacing whole-animal experi-
ments in developmental toxicology.
Nevertheless, cell-based screening methods
could be devised based on knowledge of
molecular mechanisms, pathways, and bio-
markers of toxicity.
Recently, toxicogenomics has emerged
as an attractive approach to uncover
critical molecular events altered by 
toxicants (Aardema and MacGregor 2002;
Iannaccone 2001; Nuwaysir et al. 1999).
Using microarrays and profiling tech-
niques, investigators can determine how
gene expression responses to toxic exposure
are linked to toxic outcome (phenotypic
anchoring) (Paules 2003) and identify mol-
ecular targets and biomarkers of chemically
induced toxicity. However, few microarray
studies so far have addressed developmental
toxicity (Docterman and Smith 2002) or
embryonic development (Ko 2001; Smith
and Greenﬁeld 2003). We predict that dis-
ruption of the hierarchies of signaling and
gene regulatory networks that control
embryonic development may underlie
many cases of chemically induced birth
defects. Teratogenic chemicals are therefore
likely to affect downstream gene expression
as a cause or consequence, or both, of their
adverse developmental effects. Hence,
compound-specific gene expression
responses should be possible to detect.
In this study we used spotted cDNA
microarrays to monitor global gene expres-
sion changes in response to the antiepileptic
drug valproic acid (VPA), a potent terato-
gen that most notably induces neural tube
defects (NTDs) in human, mouse, and
other vertebrate embryos (Lammer et al.
1987; Nau et al. 1991; Oberemm and
Kirschbaum 1992; Whitsel et al. 2002).
NTDs with varying penetrance can be
induced in the mouse embryo by many
chemical treatments (Copp et al. 1990) and
by the functional disruption of a plethora of
genes (Copp et al. 2003; Juriloff and Harris
2000). Induction and development of
NTDs in the mouse embryo is thus a rele-
vant model for studying chemically induced
teratogenicity. In this context, we believe
that VPA is a good model substance to be
addressed by a toxicogenomics approach.
Although the molecular mechanism by
which VPA causes NTDs remains obscure,
several genes and molecular targets have
been associated with VPA action, both in
embryos (Craig et al. 2000; Faiella et al.
2000; Wlodarczyk et al. 1996) and various
cell lines (Blaheta and Cinatl 2002; Phiel
et al. 2001; Walmod et al. 1999; Werling
et al. 2001; Yuan et al. 2001) and therapeu-
tically in epilepsy and bipolar disorders
(Gurvich and Klein 2002; Johannessen
2000). We report here the altered expres-
sion of multiple genes in mouse embryos
after treatment with VPA, and discuss some
of these genes in the light of neural tube
development and previously known VPA
actions. Employing the mouse embryo-
carcinoma cell line P19 as an in vitro model
of early pluripotent embryonic cells, we
identify further a subset of VPA-responsive
genes that may be particularly relevant
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Embryonic development is a highly coordinated set of processes that depend on hierarchies of
signaling and gene regulatory networks, and the disruption of such networks may underlie many
cases of chemically induced birth defects. The antiepileptic drug valproic acid (VPA) is a potent
inducer of neural tube defects (NTDs) in human and mouse embryos. As with many other devel-
opmental toxicants however, the mechanism of VPA teratogenicity is unknown. Using microarray
analysis, we compared the global gene expression responses to VPA in mouse embryos during the
critical stages of teratogen action in vivo with those in cultured P19 embryocarcinoma cells
in vitro. Among the identiﬁed VPA-responsive genes, some have been associated previously with
NTDs or VPA effects [vinculin, metallothioneins 1 and 2 (Mt1, Mt2), keratin 1-18 (Krt1-18)],
whereas others provide novel putative VPA targets, some of which are associated with processes
relevant to neural tube formation and closure [transgelin 2 (Tagln2), thyroid hormone receptor
interacting protein 6, galectin-1 (Lgals1), inhibitor of DNA binding 1 (Idb1), fatty acid synthase
(Fasn), annexins A5 and A11 (Anxa5, Anxa11)], or with VPA effects or known molecular actions
of VPA (Lgals1, Mt1, Mt2, Id1, Fasn, Anxa5, Anxa11, Krt1-18). A subset of genes with a tran-
scriptional response to VPA that is similar in embryos and the cell model can be evaluated as
potential biomarkers for VPA-induced teratogenicity that could be exploited directly in P19
cell–based in vitro assays. As several of the identiﬁed genes may be activated or repressed through
a pathway of histone deacetylase (HDAC) inhibition and speciﬁcity protein 1 activation, our data
support a role of HDAC as an important molecular target of VPA action in vivo. Key words:
biomarker, embryocarcinoma, galectin-1, histone deacetylase, in vitro toxicology, metalloth-
ionein, microarray, mouse embryo, neural tube defect, Sp1, teratogen, valproic acid, vinculin.
Environ Health Perspect 112:1225–1235 (2004). doi:10.1289/txg.7034 available via
http://dx.doi.org/ [Online 3 June 2004]to evaluate as potential biomarkers of VPA
teratogenicity.
Materials and Methods
Embryos
NMRI mice (B&K Universal AB,
Sollentuna, Sweden) were kept on a 12-hr
light cycle (1100–2200 hr) in the
Laboratory Animal Facility at The
Biomedical Center. Females were mated
with males for 2 hr at the end of the dark
period (0800–1000 hr). Females were
then checked for vaginal plugs, and the
midpoint of the mating period (0900 hr)
was taken as 0 days postcoitum (dpc)
Pregnant dams were treated 8.0 dpc by ip
injection of 600 mg/kg body weight
sodium valproate (Sigma Chemical Co.,
St. Louis, MO, USA) in approximately
100–200 µL 0.9% saline; control mice
received saline only. Dams were sacrificed
by cervical dislocation at 1.5 hr [RNA for
quantitative reverse transcription-poly-
merase chain reaction (RT-PCR)], 6 hr
(RNA for microarrays and quantitative
RT-PCR), or 48 hr [morphological
examination and detection of pro-
grammed cell death (PCD) by terminal
deoxynucleotidyl transferase-mediated
(dUTP) biotinylated nick end labeling
(TUNEL) staining] posttreatment. The
uterus was quickly transferred to phos-
phate-buffered saline (PBS), pH 7.4, and
the embryos were removed. For RNA
preparation, embryos were lysed in Trizol
reagent (Invitrogen, Carlsbad, CA, USA),
and stored at –80°C until further use.
Because of some within-litter and
between-litter variation in the size and
developmental stage of 8.25-dpc embryos
(6 hr posttreatment), each embryo was
quickly evaluated morphologically before
lysis, and embryos that appeared younger
than the late bud stage, as defined by
Downs and Davies (1993) were excluded.
Three pools each of treated and control
embryos were created containing embryos
from 2, 3, and 12 VPA-treated litters or 3,
4, and 12 control litters, respectively.
Detection of Programmed Cell Death
Embryos removed from control and
treated animals were fixed overnight in
4% paraformaldehyde (PF) in PBT
(0.1% Tween-20 in PBS), then processed
into 100% methanol and stored at –20°C
until use. PCD detection was performed
using the In Situ Cell Death Detection Kit,
AP (Roche Diagnostics, Indianapolis, IN,
USA) according to manufacturer instruc-
tions, with the following minor changes:
permeabilization of the embryos was
performed for 10 min in 10 µg/mL
proteinase K, followed by 4% PF for
10 min, before inactivation of the endoge-
nous peroxidase. All washing steps were
performed with PBT.
Cell Culture
P19 mouse embryocarcinoma cells (ATCC
CRL-1825; American Type Culture
Collection, Manassas, VA, USA) were cul-
tured at 37°C and 5% CO2 in Dulbecco’s
modified Eagle’s medium (National
Veterinary Institute, Uppsala, Sweden)
supplemented with 10% fetal bovine
serum (Seromed, Berlin, Germany),
1% L-glutamine, and 1% penicillin/strep-
tavidin. Cells from a subconfluent T75
flask were split 1:20 onto 10-cm plates
(Nunc, Roskilde, Denmark) in 10 mL
medium; the next day half the plates were
treated with 1 µM sodium valproate by
adding 10 µL from a 1-mM stock solu-
tion; control plates received 10 µL water.
After incubation for 24 hr, the plates were
washed twice with PBS, and the cells were
lysed with 3 mL Trizol reagent per plate
for 5 min at room temperature. Genomic
DNA was sheared by drawing the lysate
several times through a pipette until it
appeared nonviscous. Subsequently, the
lysates from all 10 treated and control
plates were pooled and stored at –80°C
until further use.
RNA Isolation
Total RNA was isolated from frozen
embryos and cells using Trizol reagent
(Invitrogen) according to manufacturer
instructions. RNA concentration was deter-
mined spectrophotometrically, and RNA
quality was checked using the Agilent 2100
Bioanalyzer and the RNA 6000 LabChip
kit (Agilent Technologies, Palo Alto, CA,
USA). The yield was approximately 1 µg
per 8.25-dpc embryo and 300 µg per con-
fluent plate of P19 cells. The A260/A280
ratios ranged from 1.8–2.0, and the
28S/18S ribosomal RNA ratios were
approximately 1.8.
cDNA Synthesis
Equal amounts of RNA from control and
treated samples were separately converted
to ﬂuorescently labeled cDNA by incorpo-
ration of the dye-conjugated nucleotides
Cyanine 3 (Cy3)-dCTP or Cy5-dCTP (or
vice versa) during first-strand cDNA syn-
thesis. Briefly, 30 µg embryonic RNA or
50 µg cellular RNA was mixed with
anchored dT17 primer, heated to 70°C and
reverse transcribed with Superscript II
reverse transcriptase (Invitrogen) for 2 hr at
42°C in the presence of 100 µM fluores-
cent nucleotide. After hydrolysis of the
RNA template, unincorporated ﬂuorescent
nucleotides were removed by ethanol
precipitation.
Microarray Hybridization
Spotted cDNA microarrays [mouse NIA
clone set arrays, slide 1 (http://www.
hgmp.mrc.ac.uk/Research/Microarray/
HGMP-RC_Microarrays/array_
description_files.jsp)], containing a subset
of 6,144 clones from approximately
15,000 developmentally expressed mouse
genes in the National Institute on Aging
(NIA) 15 K mouse cDNA clone set
(http://lgsun.grc.nia.nih.gov/cDNA/
15k.html (Tanaka et al. 2000) and spotted
in duplicate were purchased from the
Human Genome Mapping Project
Resource Centre (Hinxton, United
Kingdom; http://www.hgmp.mrc.ac.uk/).
For each hybridization, equal amounts of
fluorescently labeled cDNA were mixed
with 4 µg polyA DNA carrier and 6 µg
mouse Cot1 DNA (Invitrogen) and subse-
quently denatured by boiling in hybridiza-
tion buffer [5× sodium chloride/sodium
citrate (SSC); 6× Denhard’s solution;
60 mM Tris, pH 7.6, 0.12% sarcosyl;
48% formamide]. After cooling, 40 µL
hybridization mix was applied to the
microarray slide, and hybridization was
carried out at 50°C for 12–24 hr in a
humid hybridization chamber. After
hybridization, slides were washed on a
shaker at 55°C for 10 min with 2× SSC,
0.2% sodium dodecyl sulfate; 10 min with
2× SSC; 10 min with 0.2× SSC; 1 min
with ultrapure water; and 1 min with iso-
propanol and subsequently dried in a cen-
trifuge for 5 min at 500 × g. For embryos,
four separate hybridizations [embryo
microarray (EM) 1 through 4] addressed
both biological and technical variation,
using independent samples for EM1,
EM2, and EM3/4, and dye reversal of the
same samples (based on 12 litters) for
EM3 and EM4. For cells, four separate
hybridizations [cell microarray (CM) 1
through 4] intentionally addressed only
technical variation with duplicate dye
reversal. Control samples were labeled
with Cy3 for the odd-numbered hybridiza-
tions (i.e., EM1, EM3, CM1, CM3) and
with Cy5 for the even-numbered ones.
Microarray Data Analysis
We acquired fluorescent images of micro-
array slides using a ScanArray confocal
laser microarray scanner (Packard
BioChip Technologies, Billerica, MA,
USA). We quantified fluorescence intensi-
ties for the Cy3 and Cy5 channels using
the Spot 2.0 software package (Jain et al.
2002). We did not perform background
subtraction, as it did not improve the data
Toxicogenomics | Kultima et al.
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(log2) ratios between the two channels
were used to quantify the fold change in
relative gene expression levels between
experimental and control samples. To
remove systematic sources of variation, we
used a within-print group scaled normal-
ization method (Yang et al. 2002).
A mean value for the duplicate spots was
calculated for each array. A parametric
empirical Bayes approach (Lönnstedt and
Speed 2002) was used to identify differen-
tially expressed genes. The p-value was
fixed at 0.01, and differentially expressed
genes were defined as genes with an
absolute log of odds score value above 1.
Because no spots were excluded in the
analysis (e.g., flagged for morphologic or
other defects), and the Bayes approach
penalizes for both low absolute expression
ratio and high variance between duplicate
spots on the same or replicate slides, false
negatives may result from a bad spot on
one of the four slides. To recover such
clones, we repeated the analysis, omitting
the four arrays one by one. Genes with an
absolute log odds > 1 in any analysis were
included in the total list of genes.
Hierarchical clustering with complete
linkage and Euclidian distance as the
distance metric was computed using
J-Express 2.1 (Dysvik and Jonassen 2001).
In the hierarchical clustering, the outlying
value for any gene identified by the leave-
one-out procedure (above) was replaced in
the omitted array by the median based on
the three remaining arrays.
Quantitative Real-Time RT-PCR
Six genes identified by microarray analysis
were selected for reanalysis by quantitative
real-time RT-PCR (qPCR). We selected
the supposed housekeeping gene peptidyl-
propyl isomerase A (Ppia), also known as
cyclophilin, as the endogenous reference
because our microarray analysis indicated
that its expression is unlikely to be altered
by VPA in either mouse embryos or P19
cells. The average log2 fold change for
Ppia (represented by five clones in dupli-
cate in the NIA 1 array) was –0.08
for embryos and –0.04 for cells (data
not shown). Moreover, this gene was
previously used as endogenous reference
for gene expression analysis at the RNA
level in the context of VPA and NTDs
(Wlodarczyk et al. 1996). Primers were
designed with Primer Express software
(Applied Biosystems, Palo Alto, CA,
USA), using default setting for the
TaqMan mode, and synthesized by
Applied Biosystem. Primer sequences are
given in Table 1. For qPCR, 2 µg total
RNA was reverse transcribed in a final
volume of 100 µL using TaqMan
Reverse Transcription Reagents (Applied
Biosystems) with random hexamer primers
according to manufacturer instructions.
Reactions excluding MultiScribe Reverse
Transcriptase (Applied Biosystems) were
performed as negative controls. cDNA tar-
gets at a 100-fold final dilution were
ampliﬁed in replicate wells (four for target
genes and six for the endogenous refer-
ence), using optimized primer concentra-
tions (Table 1) in 1× qPCR Mastermix
Plus for SYBR Green I (Eurogentec,
Seraing, Belgium) in an ABI Prism 7700
Sequence Detector System (Applied
Biosystems) with the following thermal
proﬁle: 50°C for 2 min, 95°C for 10 min,
followed by 40 cycles of 15 sec at 95°C
and 1 min at 60°C. Standard curves for
each gene were obtained by amplifying (in
quadruplicate) 10-fold serial dilutions of a
reference mixture containing 25% each of
cDNA derived from VPA-treated and con-
trol embryos and cells. Outlying cycle to
threshold (CT) values were detected using
median absolute deviation (Young et al.
2003) with an arbitrary threshold > 10,
leading to the removal of one data point.
Using the standard curves, CT values for
target genes were converted to relative
input amounts and normalized to the cor-
responding values for Ppia. Differences in
the mean of normalized relative input
amounts between VPA-treated and control
samples were tested for statistical signifi-
cance using a two-tailed t-test.
Results
To monitor gene expression changes
associated with VPA teratogenicity, we
adopted conditions of early exposure
previously reported to induce NTDs in
approximately 60% of live fetuses in the
NMRI strain, as observed 18 dpc (Nau and
Löscher 1986). By administering a single
dose of sodium valproate (600 mg/kg body
weight) ip to 8.0-dpc pregnant NMRI
dams and examining embryos for develop-
mental defects 48 hr posttreatment
(10.0 dpc), we found that 22 of 42
embryos (52%) from VPA-treated dams
had different degrees of NTDs, mostly
coupled with growth retardation; 15 (36%)
were growth retarded but appeared other-
wise morphologically normal; and 5 (12%)
had diverse abnormalities such as absence
of caudal structures, cardiac dysfunction
(no heartbeats), and edema. In contrast, we
found that no control embryos from saline-
treated dams had NTDs or other apparent
developmental anomalies. Unlike several
other NTD-inducing teratogens (Mirkes
2002), we found that VPA induced no
apparent increase in apoptosis along the
tips of the neural folds (Copp et al. 2003),
as detected by TUNEL staining (Figure 1).
Instead, we found a transversal band of
apoptotic cells in the forebrain neuro-
epithelium of VPA-treated embryos
(Figure 1D), which to our knowledge has
not been reported previously and is the
subject for further investigation.
Valproic Acid–Associated Gene
Expression Changes in Mouse
Embryos
To study the gene expression response to
VPA during the susceptible stages, that is,
when VPA exerts most of its teratogenic
effect on the developing neural tube, we
extracted total RNA from pools of whole
embryos removed from control and VPA-
treated 8.25-dpc NMRI mice (6 hr
posttreatment) and subjected them to
replicated microarray analysis. To identify
differentially expressed genes, we used an
empirical Bayes model (Lönnstedt and
Speed 2002) to rank genes by their log
posterior odds of differential expression
(Figure 2A). We found that 81 clones of
the 6,144 cDNAs from the NIA 15 K
mouse cDNA clone set (Tanaka et al.
2000) represented in the NIA array 1 were
expected (log odds > 1) to be upregulated
(51 of 81) or downregulated (30 of 81) in
Toxicogenomics | Valproic acid teratogenicity
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Table 1. PCR primers.
Forward primer Reverse primer Amplicon
Gene symbol Forward primer sequence concentration (nM) Reverse primer sequence concentration (nM) length (nt)
Kpnb1 5´-GGGAATCGTCCAGGGATTG- 3´ 900 5´-AAATAAATTCTACTCTGGCTGTACCA- 3´ 900 83
Krt1-18 5´-AATCGAGGCACTCAAGGAAGAA- 3´ 300 5´-GGCATCCACTTCCACGTCA- 3´ 300 112
Lgals1 5´-GAATCTCTTCGCTTCAGCTTCA- 3´ 50 5´-CAGGTTTGAGATTCAGGTTGCT- 3´ 50 68
Mt2 5´-CGCCATGGACCCAACT- 3´ 50 5´-AGGAAGTACATTTGCATTGTTTGC-3´ 50 89
Upp 5´-TCACCATCATCCGCATTGG- 3´ 300 5´-GCCTGCTGCGTGATGACA- 3´ 900 73
Vcl 5´-TGCCAAGCAGTGCACAGATAA- 3´ 50 5´-GGTCCGGCCCAGCATAGT- 3´ 50 124
Ppia 5´-TTCCTCCTTTCACAGAATTATTCCA- 3´ 50 5´-CCGCCAGTGCCATTATGG -3´ 50 75response to VPA [Supplemental Material,
Table 1 (http://ehp.niehs.nih.gov/txg/
members/2004/7034/supplemental.pdf)].
An additional 14 clones were selected after
the leave-one-out procedure described
in “Materials and Methods” [Figure 2A;
Supplemental Material, Table 2 (http://
ehp.niehs.nih.gov/txg/members/2004/
7034/supplemental.pdf)]. Among the wide
variety of putative VPA-responsive genes
thus listed, we found that metallothio-
nein 2 (Mt2) was represented by both top-
ranked clones (Supplemental Material,
Table 1). Similarly, galectin-1 (Lgals1)
appeared to be represented by three clones;
karyopherin β1 (Kpnb1) and H3 his-
tone 3B (H3f3b) were represented by two
clones each. Approximately one-third of
the selected clones appeared to represent
uncharacterized or unknown genes
(Supplemental Material, Tables 1 and 2).
Although the identified candidate genes
belong to several functional categories,
those encoding matrix/structural proteins
appeared to be slightly overrepresented,
comprising 35% of the functionally anno-
tated clones (Supplemental Material,
Tables 1 and 2).
Valproic Acid–Associated Gene
Expression Changes in P19
Embryocarcinoma Cells
Genes that respond transcriptionally to
VPA in embryos (Supplemental Material,
Tables 1 and 2) may provide not only
important clues about mechanisms of VPA
action but also potential biomarkers of
VPA teratogenicity that could be exploited
in a cell-based screening system. Toward
this goal, we employed the pluripotent
P19 mouse embryocarcinoma cell line
(McBurney 1993) as a possibly relevant
cell model for early embryos. To identify
general VPA-responsive genes at a dose
level close to the range of therapeutic and
teratogenic concentrations while attaining
convenient and supposedly robust bioassay
conditions, total RNA was extracted from
P19 cells cultured in the presence or
absence of 1 mM VPA for 24 hr and sub-
jected to replicated microarray analysis.
Ranking the genes by their log posterior
odds of differential expression (Figure 2B),
we found 168 clones expected (log odds
> 1) to be upregulated (114 of 168)
or downregulated (54 of 168) in response
to VPA [Supplemental Material, Table 3
(http://ehp.niehs.nih.gov/txg/members/
2004/7034/supplemental.pdf)], with
16 additional clones selected by the
leave-one-out procedure [Figure 2B;
Supplemental Material, Table 4 (http://
ehp.niehs.nih.gov/txg/members/
2004/7034/supplemental.pdf)]). Again,
approximately one-third of the selected
clones appeared to represent uncharacter-
ized or unknown genes (Supplemental
Material, Tables 3 and 4). Although less
apparent than for embryos (Supplemental
Material, Tables 1 and 2), genes encoding
matrix/structural proteins again repre-
sented the largest functional category,
comprising 28% of the functionally anno-
tated clones (Supplemental Material,
Tables 3 and 4). The similar magnitude of
change in cells (Figure 2B; Supplemental
Material, Tables 3 and 4) and embryos
(Figure 2A; Supplemental Material,
Tables 1 and 2) for VPA-responsive genes
may support the relevance of the VPA
dose (1 mM) used in vitro.
Conﬁrmation of Valproic
Acid–Responsive Genes
To independently assess the altered
expression of genes identified by microar-
ray analysis, we arbitrarily selected six
genes that appeared biologically relevant
while showing diverse responses to VPA in
the two-model systems (Figure 2). Using
qPCR, we found that the selected genes
expected to be upregulated by VPA in
embryos [Lgals1, Mt2, and vinculin (Vcl)]
or cells [keratin 1-18 (Krt1-18), Lgals1,
Toxicogenomics | Kultima et al.
1228 VOLUME 112 | NUMBER 12 | August 2004 • Environmental Health Perspectives
Control VPA
B A
C D
Figure 1. NTDs and apoptosis in VPA-exposed mouse embryos. Whole 10-dpc embryos, stained with the
TUNEL technique, viewed from the right (A,B) and front (C,D). Abbreviations: ba, ﬁrst branchial arch; fb,
forebrain; mb, midbrain; nfs, neural folds. Control (A,C) and VPA-treated embryos (B,D) were removed
(48 hr posttreatment) from the uteri of NMRI dams after ip administration of sodium valproate (600 mg/kg
body weight) on 8.0 dpc. Note that VPA-exposed embryos exhibit unfused neural folds, resulting in appar-
ent signs of failed anterior neural tube closure (black arrowheads in B). Apoptotic cells (dark) are seen
along the line of neural fold fusion in control embryos (white arrowheads in C) but not in VPA-exposed
embryos (D), where instead a transversal band of apoptotic cells can be seen in the neuroepithelium of
the forebrain (D). Angles of views in C and D are indicated by white arrows in A and B, respectively.and Mt2] were significantly (p < 0.05)
induced (Figure 3). Similarly, the gene
expected to be downregulated by VPA in
cells [uridine phosphorylase (Upp)]
was significantly (p < 0.05) repressed
(Figure 3). Unlike the microarray analysis,
using qPCR we could detect a weak but
signiﬁcant (p < 0.05) induction of Krt1-18
and Vcl in embryos and cells, respectively
(Figure 3). The microarray analysis
appeared to underestimate the fold change
of expression compared with qPCR
(Figure 3), with the only exception being
Kpnb1, for which a downregulation in
embryos was not supported by qPCR
(Figure 3).
Identiﬁcation of Potential
Biomarkers of Valproic Acid
Teratogenicity
Genes that respond similarly to a teratogen
in a cultured cell model as in intact embryos
might be directly exploited as biomarkers in
an in vitro test system, using the same cell
line. To identify candidates for such poten-
tial biomarkers, we compared the results
presented in Supplemental Material,
Tables 1–4, and found 29 clones (three of
which were recovered in embryos by the
leave-one-out procedure) likely to be VPA
responsive in both embryos and P19 cells
(Table 2). These clones probably represent
no more than 25 genes, of which 16 cur-
rently have known identity (Table 2).
Among these genes are several that were top
ranked in embryos (Supplemental Material,
Table 1), such as Mt2, metallothionein 1
(Mt1), Lgals1, H3f3b, creatine kinase–brain
(Ckb), and transgelin 2 (Tagln2). The simi-
lar transcriptional response to VPA in the
cell model as in embryos strengthens the
case not only for these genes as VPA targets
in the embryo but also for a number of
other genes (Table 2; Supplemental
Material, Tables 1 and 2) such as cyto-
chrome c oxidase subunit VIIa polypeptide
2-like (Cox7a2l), ubiquitin carboxy-terminal
hydrolase L1 (Uchl1), eukaryotic translation
initiation factor 4 gamma 2 (Eif4g2), bro-
modomain containing protein 4 (Brd4),
annexin A11 (Anxa11), leukotriene B4
12-hydroxydehydrogenase (Ltb4dh),
inhibitor of DNA binding 1 (Idb1), and
fatty acid synthase (Fasn).
As we used a cutoff for differential
expression intended to minimize the num-
ber of false positives, the number of genes
with a similar transcriptional response to
VPA in the cell model as in embryos might
be underestimated in our analysis. By clus-
tering the mean log2 fold changes measured
in the eight individual microarray slides for
all 220 selected clones (i.e., clones with log
odds > 1 in either embryos or cells), we
found that most of the clones displayed in
Table 2 form two well-defined clusters of
commonly upregulated genes (clusters C1
and C2), whereas the rest of the clones are
found within two indistinct clusters of com-
monly upregulated (cluster C3) or downreg-
ulated (cluster C4) genes (Figure 4). Across
all 6,144 clones, we found that the highest
log odds score for which the transcriptional
change in embryos was not in the same
direction as in cells (disregarding the magni-
tude of change) was –0.57. Among the
122 clones above this level in embryos, the
highest and lowest log2 fold changes
detected were 0.33 and –0.31, respectively.
Applying log2 fold change > 0.3 and < –0.3
(corresponding to > 27% fold change) as the
cutoff, we could identify 41 additional
clones as putative candidates for genes with
a similar transcriptional response to VPA in
the cell model as in embryos (Figure 4).
Rapid Valproic Acid–Induced
Transcriptional Activation of the
Genes Encoding Galectin-1 and
Vinculin
Toward understanding the mechanism of
VPA action and validating candidate genes
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Figure 2. Microarray analysis of transcriptional response to VPA in (A) mouse embryos and (B) P19 mouse
embryocarcinoma cells. The log posterior odds for each clone to be differentially expressed are plotted
against the log2 fold change of expression for all cDNA clones in the NIA array 1 (see “Materials and
Methods”), based on analysis including four replicate microarray slides. The horizontal line marks the
threshold (log odds > 1) for selection of a clone as differentially expressed. Upregulated clones are
labeled red, and downregulated clones are labeled blue. The clones under the threshold line labeled red
or blue were selected (log odds > 1) by leaving out either one of the four replicate slides from the analysis
(see “Materials and Methods”). Arrows indicate clones representing the six genes Kpnb1, Krt1-18, Lgals1,
Mt2, Upp, and Vcl selected for reanalysis by qPCR (Figure 3). (A) Transcriptional response in 8.25-dpc
embryos (6 hr posttreatment) from pregnant NMRI mice after ip administration of sodium valproate
(600 mg/kg body weight) on 8.0 dpc. (B) Transcriptional response in P19 cells cultured in the presence of
1 mM sodium valproate for 24 hr.
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Figure 3. Comparison of log2-transformed expression ratios in embryos and P19 cells as determined by
microarray analysis and qPCR. 
*Signiﬁcant difference between VPA-treated and control, p < 0.05.as potentially useful biomarkers of
VPA responses, we reinvestigated the
VPA-induced transcriptional response of
selected genes (Figure 2) in mouse
embryos. VPA reaches peak levels in mouse
serum about 30 min after a single ip injec-
tion, and the half-time of VPA clearance
from mouse serum is about 1 hr (Nau et al.
1991). To investigate whether VPA at such
a peak concentration can induce a rapid
transcriptional response of selected genes,
we extracted total RNA from pools of
whole embryos removed from control and
VPA-treated pregnant NMRI dams 1.5 hr
posttreatment (dose and gestational day of
treatment as before) and subjected to
qPCR. Among the six tested genes, the
expression of Lgals1 and Vcl were signifi-
cantly (p < 0.05) induced after 1.5 hr
(Figure 5), which may support indepen-
dently the VPA responsiveness of these
two genes.
Discussion
Although several modes of VPA action have
been proposed [e.g., histone deacetylase
(HDAC) and protein kinase (PKC) inhibi-
tion, extracellular signal-regulated kinase
(ERK) and activator protein-1 (AP-1) acti-
vation, and effects on the actin cytoskele-
ton] (Blaheta and Cinatl 2002; Gurvich
and Klein 2002; and Walmod et al. 1999),
the mechanism of VPA teratogenicity
remains poorly understood. In this study
we used microarrays to monitor gene
expression changes in response to VPA dur-
ing stages critical to VPA-induced NTDs in
the mouse embryo. Some of the more than
70 putative VPA target genes thus identi-
ﬁed (Supplemental Material, Table 1) have
previously been directly or indirectly linked
to VPA effects or to NTDs or processes rel-
evant to neural tube formation and closure,
but most appear to be novel candidates.
Moreover, we propose that many of these
genes by virtue of their similar expression
changes in embryos and cultured P19
mouse embryocarcinoma cells (Table 2;
Figure 4) could be directly exploited as
potential biomarkers of VPA action in cell-
based assays.
To date, mouse embryos have not been
extensively studied by microarray analysis
(Carter et al. 2003; Smith and Greenfield
2003), partly because of their small size and
limited RNA content. Here we overcome
this limitation by pooling whole embryos
from several similarly treated mice. Despite
our primary goal to identify candidate genes
that may be VPA targets in disturbed neural
tube closure, the use of whole embryos
rather than isolated neural tubes may be
warranted for at least three reasons. First,
VPA accumulates in the neuroepithelium
(Dencker et al. 1990), which constitutes a
major region of the mouse embryo during
the stages investigated. Second, neural tube
closure can be inﬂuenced by genes that are
mostly or only expressed outside the neural
tube [e.g., cartilage homeoprotein 1
(Cart1), Twist, and sonic hedgehog (Shh)]
(Copp et al. 1990). Third, potential dissec-
tion artifacts (Diaz et al. 2003) are mini-
mized. In addition, bulk approaches such as
the pooling strategy we used in this study
may be warranted to allow the study of
gene expression changes during early stages
of neural tube development without the
need to know which individual embryos
will subsequently develop NTDs in
response to the VPA treatment (50–60%).
An unfavorable consequence of pooling
whole embryos from multiple litters, how-
ever, is that we dilute the expression
changes for those genes expressed only in
certain deﬁned regions of the embryo, such
as distinct areas of the neural tube, as well
as for any genes that may be responding to
VPA mostly or only in those embryos that
will become malformed. To some degree,
this may account for why we are able to
identify fewer differentially expressed genes
in the embryo (Supplemental Material,
Toxicogenomics | Kultima et al.
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Table 2. Genes responding transcriptionally to VPA in embryos and P19 cells.
Embryos Cells
Log Log2 fold Log Log2 fold
NIA EST ID Gene symbola Gene namea odds change odds change Functionb
H3014B09 Anxa11 Annexin A11 2.2 0.58 7.1 0.97 Matrix/structural proteins
H3056G04 Brd4 Bromodomain containing 4 2.5 0.76 8.6 0.81 Signal transduction
H3055H05 Carhsp1 Calcium-regulated heat stable protein 1 1.1 0.42 3.6 0.59 ?
H3007E10 Ckb Creatine kinase, brain 8.2 1.45 10.0 1.01 Matrix/structural proteins
H3024F03 Cox7a2l Cytochrome c oxidase subunit VIIa polypeptide 2-like 3.0 0.50 4.0 0.52 ?
H3027A06 Eif4g2 Eukaryotic translation initiation factor 4 gamma 2 2.7 –0.48 2.3 –0.44 Protein synthesis/translational control
H3011D03 Fasn Fatty acid synthase 1.7 –0.68 1.7 –0.46 Matrix/structural proteins
H3054D02 H3f3b H3 histone, family 3B 5.9 0.71 8.4 0.81 Transcription/chromatin
H3013D08 H3f3b H3 histone, family 3B 5.7 0.66 6.9 0.92 Transcription/chromatin
H3003F10 Idb1 Inhibitor of DNA binding 1 1.8 0.51 5.2 0.65 Transcription/chromatin
H3009D05 Lgals1 Lectin, galactose binding, soluble 1 8.7 1.02 6.4 0.86 Matrix/structural proteins
H3003A03 Lgals1 Lectin, galactose binding, soluble 1 4.2 0.88 7.4 0.84 ?
H3022G07 Lgals1 Lectin, galactose binding, soluble 1 3.1 0.67 3.1 0.58 Matrix/structural proteins
H3040C04 Ltb4dh Leukotriene B4 12-hydroxydehydrogenase 1.8 0.69 9.0 1.34 ?
H3020C02 Mt1 Metallothionein 1 10.3 1.26 5.4 0.71 Heat shock/stress
H3013D11 Mt2 Metallothionein 2 11.6 1.58 2.2 0.90 Heat shock/stress
H3010E09 Mt2* Metallothionein 2* 11.4 1.60 4.0 0.67 Heat shock/stress**
H3012D03 Pmf1 Polyamine-modulated factor 1 1.6 –0.53 4.1 –0.66 ?
H3031E04 Rpo1-4 RNA polymerase 1-4 1.8 –0.46 3.5 –0.64 Protein synthesis/translational control
H3017H12 Tagln2 Transgelin 2 4.4 0.64 10.3 1.09 ?
H3059F01 Uchl1 Ubiquitin carboxy-terminal hydrolase L1 2.9 0.93 1.2 0.59 ?
H3010C05 1110007A10Rik RIKEN cDNA 1110007A10 gene 1.3 0.38 1.5 0.41 ?
H3031A04 2410016F19Rik RIKEN cDNA 2410016F19 gene 3.0 –0.74 2.7 –0.46 ?
H3009E04 2410043F08Rik RIKEN cDNA 2410043F08 gene 1.2 0.64 2.6 0.56 ?
H3003F11 9130023P14Rik RIKEN cDNA 9130023P14 gene 1.6 0.63 3.3 0.85 Matrix/structural proteins
H3004B11 A930014C21Rik RIKEN cDNA A930014C21 gene 2.8 0.51 5.0 0.81 ?
H3022F11 ? ? 1.9 –0.49 1.2 –0.46 ?
H3005E03 ? ? 1.6 0.73 10.6 1.29 ?
H3013C04 ? ? 1.3 0.44 5.1 0.63 ?**
Abbreviations: ?, unknown genes and/or functions; EST, expressed sequence tag; ID, identiﬁer. 
aGene symbols are from the NIA web site (http://lgsun.grc.nia.nih.gov/cDNA/15k.html) as of 30 May 2003, except where indicated by asterisk. bGene names are from SOURCE
(http://source.stanford.edu/cgi-bin/source/SourceSearch) as of 19 September 2003, except where indicated by asterisk. *Annotation by tBLASTx (http://www.ncbi.nlm.nih.gov/BLAST/).
**Annotation performed manually, i.e., computer-assigned functions of unknown genes were removed, or known functions for genes identiﬁed by tBLASTx were added.Toxicogenomics | Valproic acid teratogenicity
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Figure 4. Hierarchical two-way clustering of all 220 genes expected to be tran-
scriptionally responsive to VPA (log odds > 1) in either embryos (Supplemental
Material, Tables 1 and 2) or cells (Supplemental Material, Tables 3 and 4), using
the mean log2 fold change of expression (represented by a blue–red color scale;
bottom) on both sets of four replicate microarray slides (embryos: EM1–EM4 and
cells: CM1–CM4; see “Materials and Methods”). The thick vertical lines to the
right of the heat map mark the 29 clones with log odds > 1 that respond similarly
to VPA in both embryos and cells (black), and the additional 41 clones with log2
fold changes > 0.3 or < –0.3 in both embryos and cells (gray). At the right, four
discernible clusters (C1–C4) are marked with thin vertical lines.Tables 1 and 2) than in the P19 cell line
(Supplemental Material, Tables 3 and 4).
The formation and closure of the
neural tube is a highly coordinated set of
events that involves a multitude of morpho-
genetic movements and regulated cell
behavior (Copp et al. 2003; DeSesso et al.
1999; Smith and Schoenwolf 1997).
Several null mutations for actin-regulating
genes have been reported to be associated
with NTDs (Copp et al. 2003), illustrating
that proper regulation of cell shape and cell
movements is crucial for neurulation
processes to occur normally. In this study,
we found that the expression of the gene
encoding Vcl is rapidly induced in embryos
after VPA treatment (Figure 5). Vinculin,
which is essential for neural tube closure
(Xu et al. 1998), is an actin-binding pro-
tein associated with focal adhesions
(De Arcangelis and Georges-Labouesse
2000) and has previously been reported to
be increased in such points of integrin-
mediated cell–matrix interactions after
VPA treatment in vitro (Walmod et al.
1999). Some integrins and extracellular
matrix components, along with compo-
nents downstream of integrin signaling,
also appear to be essential for neural tube
closure (Brouns et al. 2000; De Arcangelis
and Georges-Labouesse 2000; Juriloff and
Harris 2000). Adverse effects of VPA on
the dynamics of the actin cytoskeleton
may therefore contribute to VPA terato-
genicity, as has been previously suggested
(Walmod et al. 1999). The supposed actin
dependency of anterior but not posterior
neuropore closure in mouse embryos
(Ybot-Gonzalez and Copp 1999) could
thus explain why exencephaly is the domi-
nant NTD observed in VPA-exposed mice
(Nau et al. 1991). Although emerging as a
conceivable VPA target from a mechanistic
point of view, vinculin might be less
straightforward to exploit as a biomarker of
VPA effects given the weak response in our
cell model (Figure 3). Conversely, we
found that the expression of the gene
encoding Tagln2, an actin-binding protein
with the ability to cross-link actin ﬁlaments
(Shapland et al. 1993), was induced, and
the genes encoding spermidine synthase
(Srm), an actin-regulating protein (Caruso
et al. 1994), and thyroid hormone receptor
interactor 6 (Trip6), a focal adhesion-
binding protein with nuclear shuttling
activity, were repressed in response to VPA
in both embryos and P19 cells (Table 2;
Figure 4). Our ﬁndings may support a role
of integrin-mediated actin regulation in
VPA teratogenicity, even though we were
unable to observe any apparent reorganiza-
tion of the actin cytoskeleton, as visualized
by phalloidin staining (data not shown), in
P19 cells treated with VPA at the present
concentration (1 mM).
Along these lines, we found the
expression of the gene Lgals1, which encodes
the β-galactoside–binding protein galectin-1
(Barondes et al. 1994), was induced by VPA
in both embryos and cells (Table 2;
Figure 4). Galectin-1 is a multifunctional
homodimeric lectin whose extracellular and
intracellular activities are thought to regulate
cellular processes as diverse as cell–matrix
interactions, signal transduction, migration,
differentiation, proliferation, apoptosis, and
RNA splicing (Hughes 2001; Liu et al.
2002; Perillo et al. 1998). Binding of
galectin 1 to the extracellular portion of
β1 integrin (Moiseeva et al. 2003) may
modulate cell adhesion to extracellular
matrix components such as ﬁbronectin and
laminin and activate downstream events of
integrin signaling (Giancotti and Ruoslahti
1999). Intracellularly, galectin-1 appears to
be recruited by the G-protein H-Ras, a
membrane-associated transducer of integrin
and receptor tyrosine kinase signaling
(Giancotti and Ruoslahti 1999), to stabilize
its active guanosine triphosphate (GTP)-
bound state and membrane anchorage in
microdomains segregated from lipid rafts
(Hancock 2003). Overexpression of
galectin-1 and its binding to H-Ras-GTP
may thus enhance signaling through Raf1
and the ERK pathway (Hancock 2003),
which along with the downstream effector
AP-1 is activated by VPA (Blaheta and
Cinatl 2002; Yuan et al. 2001).
The rapid activation of the Lgals1 gene
(Figure 5) indicates that VPA may act at
the immediate level of the Lgals1 pro-
moter. Because VPA is a direct HDAC
inhibitor (Göttlicher et al. 2001;
Phiel et al. 2001) and because other
HDAC inhibitors such as butyrate and
trichostatin A (TSA) induce galectin-1
expression at the transcriptional level (Lu
and Lotan 1999), it is likely that VPA
induces expression at the Lgals1 promoter
by virtue of its activity as an HDAC
inhibitor. As a short-chain carboxylic acid
structurally related to VPA, butyric acid
has been reported to be teratogenic in
whole-embryo culture (Coakley et al.
1986), and the structurally unrelated TSA
has been reported to induce NTDs in
mouse embryos in vitro (Svensson et al.
1998).  Hdac1–/–mouse embryos die
severely growth retarded before 10.5 dpc,
and Hdac1–/– embryonic stem cells prolif-
erate poorly, indicating that the silencing
of gene expression by Hdac1 is essential
for cell proliferation during embryonic
development (Lagger et al. 2002). As
shown for other HDAC inhibitors, the
effects on gene expression by VPA may
depend on the transcription factor speci-
ficity protein 1 (Sp1) (Arinze and Kawai
2003), which binds to GC-rich promoter
elements (Suske 1999). The DNA-binding
activity of Sp1 is modulated by direct
interaction with HDAC (Doetzlhofer et al.
1999), and it has been suggested that VPA
and TSA inhibit the activity of HDAC by
interfering with its catalytic site
(Göttlicher et al. 2001). Butyrate may
affect Sp1-mediated induction of Lgals1
transcription by a mechanism, as yet
unknown, distinct from that of TSA (Lu
and Lotan 1999). It is therefore tempting
to speculate that VPA, by virtue of its
known blocking of TSA binding to
HDAC (Göttlicher et al. 2001) and struc-
tural similarity to butyric acid, could act
by either or both of these mechanisms to
induce gene expression at the Lgals1 pro-
moter. Hence, the activation of the
ERK/AP-1 pathway by VPA could occur
downstream of HDAC inhibition and
Sp1-induced galectin-1 overexpression.
The transcriptional induction we found
in embryos and P19 cells (Table 2;
Figure 4) of the genes encoding the metal-
regulating proteins Mt1 and Mt2 may also
be attributed to the HDAC-inhibitory
activity of VPA (Marks et al. 2003), as
these genes may be activated through
Sp1 derepression (Ogra et al. 2001) or
chromatin-opening histone acetylation
(Ghoshal et al. 2002). Butyrate increases
mRNA levels of both these genes in
embryocarcinoma cell lines (Andrews and
Adamson 1987), and VPA increases the
level of metallothionein protein in the liver
of mice (Kaji and Mikawa 1991) and preg-
nant rats (Bui et al. 1998; Keen et al.
1989), causing zinc depletion in the
embryos. In the present study we found
induced metallothionein expression also in
the embryo after maternal VPA administra-
tion (Table 2), possibly exacerbating the
depletion of Zn2+ available for develop-
mental processes. It is conceivable that
disturbed Zn2+ availability could affect,
Toxicogenomics | Kultima et al.
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Figure 5. Transcriptional response in embryos
1.5 and 6 hr posttreatment after ip administration
of sodium valproate (600 mg/kg body weight) on
8.0 dpc, as determined by qPCR. 
*Significant difference between VPA-treated and con-
trol, p < 0.05.among other processes, the activity of zinc
finger–containing transcription factors
essential for normal neural tube develop-
ment, such as Yin Yang 1 (YY1) (Donohoe
et al. 1999) and Zic1 through Zic3
(Klootwijk et al. 2000; Nagai et al. 1997,
2000). Because of this evidence and the
association between Zn deficiency and
human NTDs (Zimmerman 1984), dis-
rupted Zn homeostasis may appear as an
attractive mechanism for VPA teratogenesis
despite some evidence against Zn defi-
ciency as the cause of VPA-induced exen-
cephaly in the mouse embryo (Wegner
et al. 1990). Copper depletion could also
be the culprit because metallothionein
binds Cu2+ more strongly than
Zn2+ (Holt et al. 1980), VPA treatment
enhances copper excretion (Kuzuya et al.
2002), and knockout of the copper trans-
porter Ctr1 results in NTDs (Lee et al.
2001). An obvious weakness with the con-
cept of VPA teratogenesis being mediated
by metallothionein induction is that Mt1
and Mt2 are coordinately induced by such
a wide variety of stressors (Andrews 2000)
that they could reasonably be dismissed as
being part of a general stress response
(Brady 1981) rather than being linked to a
speciﬁc compound such as VPA. However,
exposure to an HDAC inhibitor may not
be automatically stressful in this regard.
TSA alone, for example, activates the MT1
promoter in some cell types (Dressel et al.
2000) but not in others (Ghoshal et al.
2002).
Metallothioneins are also potent
antioxidants (Andrews 2000). The role of
reactive oxygen species (ROS) in develop-
mental toxicity is well documented (Fantel
1996). Their role in VPA teratogenicity,
however, remains unclear, although ROS
production has been detected in response
to VPA in vitro (Na et al. 2003), and VPA-
induced NTDs are prevented by the
antioxidant vitamin E in vivo (Al Deeb
et al. 2000). It is therefore interesting that
we found the gene Ltb4dh, which encodes
a protein with antioxidant properties (Dick
et al. 2001), induced by VPA in both
embryos and P19 cells (Table 2).
In addition to the known developmental
importance of a gene, as determined by the
phenotypes of knockout mice, a gene’s puta-
tive involvement in neural tube develop-
ment may also be inferred from its
expression domain. For example, we ﬁnd a
reduced expression of the gene Fasn in both
embryos and P19 cells (Table 2). This gene
is normally expressed in developmentally
active regions such as the dorsal neural folds
of the closing neural tube (Chirala et al.
2003). If Fasn protein is crucial for these
processes, VPA-induced downregulation of
Fasn gene expression could evidently disturb
them. Considering that homozygous Fasn
knockout mice die before implantation and
also that most of the Fasn+/– mice die or
develop abnormally (Chirala et al. 2003),
Fasn emerges as a putative target for terato-
gen action. Intriguingly, the Fasn gene is
transcriptionally regulated by Sp1 (Fukuda
et al. 1999), again pointing toward HDAC
inhibition as a potential cause for the VPA
responsiveness.
Another way by which a gene may be
associated with NTDs is if its product acts
in a pathway essential for neural tube devel-
opment. Bone morphogenetic protein
(BMP) signaling is likely to represent such a
pathway, given that knockout of both the
BMP signaling transducer Smad5 (Chang
et al. 1999) and the BMP inhibitor noggin
(McMahon et al. 1998) results in NTDs
(mice homozygous for null alleles of the
genes encoding BMP-2, BMP-4, and BMP
receptor type IA die before or around neu-
rulation). Members of the inhibitor of
DNA binding family, which are dominant
negative regulators of basic helix–loop–helix
transcription factors with diverse cellular
effects, are among the most important
downstream targets and effectors of BMP
signaling (Miyazono and Miyazawa 2002).
The enhanced expression of the Idb1 gene
we observed in both VPA-treated embryos
and cells (Table 2) could therefore reﬂect or
mimic disturbed BMP signaling. Idb1 gene
activation by Smads is inhibited by YY1
(Kurisaki et al. 2003), the repressive activity
of which may be mediated by interactions
with HDAC1 (Yang et al. 1996) and Sp1
(Lee et al. 1993) through a GC-rich
Sp1/YY1-binding enhancer site in the Idb1
gene (Lopez-Rovira et al. 2002). HDAC
inhibition, by relieving both Sp1 and YY1
repression, may therefore cause dysregula-
tion of Idb1 gene activity.
It is striking that so many of the
identiﬁed VPA-responsive genes encode for
proteins that are multifunctional or have
integrative activities, galectin-1 being an
obvious example. Similar to galectin-1,
members of the annexin family have intra-
cellular, extracellular, and membrane-
bound functions and are involved in
cell–matrix interactions, cell growth, and
differentiation (Seaton and Dedman 1998).
The VPA-induced transcriptional induction
of annexin A5 (Anxa5) and Anxa11 we
detect in both embryos and cells (Table 2)
may depend on HDAC inhibition, as the
mouse Anxa5 and the human ANXA11
genes have Sp1 sites in their promoters
(Bances et al. 2000; Rodriguez-Garcia et al.
1999). Interestingly, annexins may be
substrates for and negatively regulate
phosphatidylinostiol-dependent PKC
activity, the inhibition of which is an estab-
lished VPA effect (Blaheta and Cinatl
2002). Kpnb1 (also known as importin-β)
may also be categorized as multifunctional,
as it is a nuclear transport factor with addi-
tional roles as a chaperone in the cytoplasm
and during mitosis (Jäkel et al. 2002).
Although Kpnb1 is a gene whose expression
has been reported to be downregulated by
HDAC inhibition (Marks et al. 2003), our
present data do not provide conclusive evi-
dence for its repression by VPA in mouse
embryos (Supplemental Material, Table 1;
Figure 3). Trip6 is another good example of
a protein with dual localization and func-
tion. In addition to its association with
focal adhesions, it functions as an intra-
cellular signaling molecule that shuttles
between the cell surface and the nucleus
(Wang et al. 1999), where it acts as a tran-
scription factor.
Recently, the expression of Trip6, along
with Eif4g2, and particularly Upp, was
reported to be stem cell speciﬁc (Ramalho-
Santos et al. 2002). Essentially, these genes
were identified as part of a set of genes
defining “stemness,” that is, promotion of
cell self-renewal and suppression of differ-
entiation. It is therefore interesting that we
found the expression of Eif4g2 and Trip 6
downregulated in response to VPA in P19
cells and embryos (Table 2; Figure 4) and
the expression of Upp downregulated in
P19 cells (Figure 3; Supplemental Material,
Table 4). Similarly, Krt1-18 has been
reported as a marker of stem cell differenti-
ation (Kelly and Rizzino 2000). Increased
expression of the Krt1-18 gene has recently
been reported to be a marker for VPA-
induced differentiation in F9 mouse
embryocarcinoma cells (Werling et al.
2001), a cell line similar to P19 cells. An
Sp1 site in the Krt1-18 promoter is impor-
tant for the expression of this gene
(Gunther et al. 1995), which is also acti-
vated by butyrate and TSA in F9 cells
(Miyashita et al. 1994), suggesting that
VPA may activate Krt1-18 expression
through HDAC inhibition. Our data sup-
port that Krt1-18 and the co-regulated
Krt2-8 gene may be VPA inducible in cul-
tured embryocarcinoma cells (Figure 3;
Supplemental Material, Table 2) and that
Krt1-18 may respond weakly in the embryo
(Figure 3).
We conclude that microarray-based
toxicogenomics approaches may be useful
for identifying target genes and biomarkers
of developmental toxicity. By linking gene
expression changes to toxic outcome, we
detected alterations in gene expression at
the level of whole embryos that may be fur-
ther investigated in terms of hypotheses
about mechanisms underlying defective
Toxicogenomics | Valproic acid teratogenicity
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Trip6, Mt1, Mt2, Fasn, Id1). By comparing
gene expression changes in whole embryos
with those in a cultured cell model, we
defined a subset of VPA-responsive genes
that may be evaluated as potential bio-
markers of VPA teratogenicity (Lgals1, Id1,
Fasn, Anxa5). A recurrent theme among
these genes, as well as for others (Mt1,
Anxa11, Krt1-18), is that they may be acti-
vated or repressed through HDAC inhibi-
tion and Sp1 activation, indicating that
HDAC may be a primary molecular target
of VPA action in vivo. It remains to be
determined to what extent the disruptive
effect of VPA on neural tube development
may be compounded from the deregulation
of a wide variety of target genes acting
downstream of HDAC inhibition. Our
toxicogenomics approach provides a frame-
work for further studies of developmental
toxicity induced by VPA and other chemi-
cals, addressing parameters such as dose,
time, and duration of exposure, and genetic
susceptibility. In summary, the parallel use
of in vivo and in vitro models in conjunc-
tion with global expression profiling
emerges as a relevant approach toward the
identiﬁcation of biomarkers associated with
toxicity after exposure to a wide variety of
environmental teratogens.
REFERENCES
Aardema MJ, MacGregor JT. 2002. Toxicology and
genetic toxicology in the new era of “toxico-
genomics”: impact of “-omics” technologies.
Mutat Res 499(1):13–25.
Al Deeb S, Al Moutaery K, Arshaduddin M, Tariq M.
2000. Vitamin E decreases valproic acid induced
neural tube defects in mice. Neurosci Lett
292(3):179–182.
Andrews GK. 2000. Regulation of metallothionein
gene expression by oxidative stress and metal
ions. Biochem Pharmacol 59(1):95–104.
Andrews GK, Adamson ED. 1987. Butyrate selectively
activates the metallothionein gene in teratocarci-
noma cells and induces hypersensitivity to metal
induction. Nucleic Acids Res 15(13):5461–5475.
Arinze IJ, Kawai Y. 2003. Sp family of transcription fac-
tors is involved in valproic acid-induced expres-
sion of galphai2. J Biol Chem 278(20):17785–17791.
Bances P, Fernandez MR, Rodriguez-Garcia MI,
Morgan RO, Fernandez MP. 2000. Annexin A11
(ANXA11) gene structure as the progenitor of
paralogous annexins and source of orthologous
cDNA isoforms. Genomics 69(1):95–103.
Barondes SH, Cooper DN, Gitt MA, Leffler H. 1994.
Galectins. Structure and function of a large family
of animal lectins. J Biol Chem 269(33):20807–20810.
Blaheta RA, Cinatl J Jr. 2002. Anti-tumor mechanisms
of valproate: a novel role for an old drug. Med
Res Rev 22(5):492–511.
Brady FO. 1981. Synthesis of rat hepatic zinc thionein
in response to the stress of sham operation. Life
Sci 28(14):1647–1654.
Brouns MR, Matheson SF, Hu KQ, Delalle I,
Caviness VS, Silver J, et al. 2000. The adhesion
signaling molecule p190 RhoGAP is required for
morphogenetic processes in neural develop-
ment. Development 127(22):4891–4903.
Bui LM, Taubeneck MW, Commisso JF, Uriu-Hare JY,
Faber WD, Keen CL. 1998. Altered zinc metabo-
lism contributes to the developmental toxicity of
2-ethylhexanoic acid, 2-ethylhexanol and val-
proic acid. Toxicology 126(1):9–21.
Carter MG, Hamatani T, Sharov AA, Carmack CE,
Qian Y, Aiba K, et al. 2003. In situ-synthesized
novel microarray optimized for mouse stem cell
and early developmental expression profiling.
Genome Res 13(5):1011–1021.
Caruso A, Pellati A, Bosi G, Arena N, Stabellini G. 1994.
Effects of spermidine synthase inhibition on
cytoskeletal organization in cultured chick embryo
ﬁbroblasts. Eur J Histochem 38(3):245–252.
Chang H, Huylebroeck D, Verschueren K, Guo Q,
Matzuk MM, Zwijsen A. 1999. Smad5 knockout
mice die at mid-gestation due to multiple embry-
onic and extraembryonic defects. Development
126(8):1631–1642.
Chirala SS, Chang H, Matzuk M, Abu-Elheiga L,
Mao J, Mahon K, et al. 2003. Fatty acid synthesis
is essential in embryonic development: fatty acid
synthase null mutants and most of the hetero-
zygotes die in utero. Proc Natl Acad Sci USA
100(11):6358–6363.
Coakley ME, Rawlings SJ, Brown NA. 1986. Short-
chain carboxylic acids, a new class of teratogens:
studies of potential biochemical mechanisms.
Environ Health Perspect 70:105–111.
Copp A, Brook FA, Estibeiro JP, Shum AS, Cockroft DL.
1990. The embryonic development of mammalian
neural tube defects. Progr Neurobiol 35:363–403.
Copp AJ, Greene ND, Murdoch JN. 2003. The genetic
basis of mammalian neurulation. Nat Rev Genet
4(10):784–793.
Craig JC, Bennett GD, Miranda RC, Mackler SA,
Finnell RH. 2000. Ribonucleotide reductase sub-
unit R1: a gene conferring sensitivity to valproic
acid-induced neural tube defects in mice.
Teratology 61(4):305–313.
De Arcangelis A, Georges-Labouesse E. 2000.
Integrin and ECM functions: roles in vertebrate
development. Trends Genet 16(9):389–395.
Dencker L, Nau H, D’Argy R. 1990. Marked accumula-
tion of valproic acid in embryonic neuroepithe-
lium of the mouse during early organogenesis.
Teratology 41(6):699–706.
DeSesso JM, Scialli AR, Holson JF. 1999. Apparent
lability of neural tube closure in laboratory ani-
mals and humans. Am J Med Genet 87(2):143–162.
Diaz E, Yang YH, Ferreira T, Loh KC, Okazaki Y,
Hayashizaki Y, et al. 2003. Analysis of gene
expression in the developing mouse retina. Proc
Natl Acad Sci USA 100(9):5491–5496.
Dick RA, Kwak MK, Sutter TR, Kensler TW. 2001.
Antioxidative function and substrate speciﬁcity of
NAD(P)H-dependent alkenal/one oxidoreductase.
A new role for leukotriene B4 12-hydroxydehydro-
genase/15-oxoprostaglandin 13-reductase. J Biol
Chem 276(44):40803–40810.
Docterman KE, Smith SM. 2002. Of meis and men:
lessons from a microarray study of teratogen
action. Teratology 66(5):217–223.
Doetzlhofer A, Rotheneder H, Lagger G, Koranda M,
Kurtev V, Brosch G, et al. 1999. Histone deacety-
lase 1 can repress transcription by binding to
Sp1. Mol Cell Biol 19(8):5504–5511.
Donohoe ME, Zhang X, McGinnis L, Biggers J, Li E,
Shi Y. 1999. Targeted disruption of mouse
Yin Yang 1 transcription factor results in peri-
implantation lethality. Mol Cell Biol 19(10):
7237–7244.
Downs KM, Davies T. 1993. Staging of gastrulating
mouse embryos by morphological landmarks in
the dissecting microscope. Development
118(4):1255–1266.
Dressel U, Renkawitz R, Baniahmad A. 2000.
Promoter specific sensitivity to inhibition of his-
tone deacetylases: implications for hormonal
gene control, cellular differentiation and cancer.
Anticancer Res 20(2A):1017–1022.
Dysvik B, Jonassen I. 2001. J-Express: exploring gene
expression data using Java. Bioinformatics
17(4):369–370.
Faiella A, Wernig M, Consalez GG, Hostick U,
Hofmann C, Hustert E, et al. 2000. A mouse model
for valproate teratogenicity: parental effects,
homeotic transformations, and altered HOX
expression. Hum Mol Genet 9(2):227–236.
Fantel AG. 1996. Reactive oxygen species in develop-
mental toxicity: review and hypothesis. Teratology
53(3):196–217.
Fukuda H, Noguchi T, Iritani N. 1999. Transcriptional
regulation of fatty acid synthase gene and ATP
citrate-lyase gene by Sp1 and Sp3 in rat hepato-
cytes(1). FEBS Lett 464(3):113–117.
Ghoshal K, Datta J, Majumder S, Bai S, Dong X,
Parthun M, et al. 2002. Inhibitors of histone
deacetylase and DNA methyltransferase synergis-
tically activate the methylated metallothionein I
promoter by activating the transcription factor
MTF-1 and forming an open chromatin structure.
Mol Cell Biol 22(23):8302–8319.
Giancotti FG, Ruoslahti E. 1999. Integrin signaling.
Science 285(5430):1028–1032.
Göttlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A,
Giavara S, et al. 2001. Valproic acid defines a
novel class of HDAC inhibitors inducing dif-
ferentiation of transformed cells. EMBO J
20(24):6969–6978.
Gunther M, Frebourg T, Laithier M, Fossar N,
Bouziane-Ouartini M, Lavialle C, et al. 1995. An
Sp1 binding site and the minimal promoter con-
tribute to overexpression of the cytokeratin 18
gene in tumorigenic clones relative to that in
nontumorigenic clones of a human carcinoma
cell line. Mol Cell Biol 15(5):2490–2499.
Gurvich N, Klein PS. 2002. Lithium and valproic acid:
parallels and contrasts in diverse signaling con-
texts. Pharmacol Ther 96(1):45–66.
Hancock JF. 2003. Ras proteins: different signals
from different locations. Nat Rev Mol Cell Biol
4(5):373–384.
Holt D, Magos L, Webb M. 1980. The interaction of
cadium-induced rat renal metallothionein with
bivalent mercury in vitro. Chem Biol Interact
32(1–2):125–135.
Hughes RC. 2001. Galectins as modulators of cell
adhesion. Biochimie 83(7):667–676.
Iannaccone PM. 2001. Toxicogenomics: “the call of the
wild chip.” Environ Health Perspect 109(1):A8–A11.
Jain AN, Tokuyasu TA, Snijders AM, Segraves R,
Albertson DG, Pinkel D. 2002. Fully automatic
quantiﬁcation of microarray image data. Genome
Res 12(2):325–332.
Jäkel S, Mingot JM, Schwarzmaier P, Hartmann E,
Görlich D. 2002. Importins fulfils a dual function
as nuclear import receptors and cytoplasmic
chaperones for exposed basic domains. EMBO J
21(3):377–386.
Johannessen CU. 2000. Mechanisms of action of
valproate: a commentatory. Neurochem Int
37(2–3):103–110.
Juriloff DM, Harris MJ. 2000. Mouse models for
neural tube closure defects. Hum Mol Genet
9(6):993–1000.
Toxicogenomics | Kultima et al.
1234 VOLUME 112 | NUMBER 12 | August 2004 • Environmental Health PerspectivesKaji M, Mikawa H. 1991. Induction of metallothionein
in mouse liver by valproic acid. Toxicology
69(2):143–149.
Keen CL, Peters JM, Hurley LS. 1989. The effect of val-
proic acid on 65Zn distribution in the pregnant rat.
JNutr 119(4):607–611.
Kelly DL, Rizzino A. 2000. DNA microarray analyses of
genes regulated during the differentiation of embry-
onic stem cells. Mol Reprod Dev 56(2):113–123.
Klootwijk R, Franke B, van der Zee CE, de Boer RT,
Wilms W, Hol FA, et al. 2000. A deletion encom-
passing Zic3 in bent tail, a mouse model for
X-linked neural tube defects. Hum Mol Genet
9(11):1615–1622.
Ko MS. 2001. Embryogenomics: developmental biology
meets genomics. Trends Biotechnol 19(12):511–518.
Kurisaki K, Kurisaki A, Valcourt U, Terentiev AA,
Pardali K, Ten Dijke P, et al. 2003. Nuclear factor
YY1 inhibits transforming growth factor beta- and
bone morphogenetic protein-induced cell differ-
entiation. Mol Cell Biol 23(13):4494–4510.
Kuzuya T, Amioka K, Nabeshima T. 2002. Valproic
acid increases biliary copper excretion in the rat.
Epilepsy Res 51(3):279–285.
Lagger G, O’Carroll D, Rembold M, Khier H, Tischler J,
Weitzer G, et al. 2002. Essential function of histone
deacetylase 1 in proliferation control and CDK
inhibitor repression. EMBO J 21(11):2672–2681.
Lammer EJ, Sever LE, Oakley GP Jr. 1987. Teratogen
update: valproic acid. Teratology 35(3):465–473.
Lee J, Prohaska JR, Thiele DJ. 2001. Essential role for
mammalian copper transporter Ctr1 in copper
homeostasis and embryonic development. Proc
Natl Acad Sci USA 98(12):6842–6847.
Lee JS, Galvin KM, Shi Y. 1993. Evidence for physical
interaction between the zinc-ﬁnger transcription
factors YY1 and Sp1. Proc Natl Acad Sci USA
90(13):6145–6149.
Liu FT, Patterson RJ, Wang JL. 2002. Intracellular
functions of galectins. Biochim Biophys Acta
1572(2–3):263–273.
Lönnstedt I, Speed TP. 2002. Replicated microarray
data. Statist Sinica 12:31–46.
Lopez-Rovira T, Chalaux E, Massague J, Rosa JL,
Ventura F. 2002. Direct binding of Smad1 and
Smad4 to two distinct motifs mediates bone mor-
phogenetic protein-specific transcriptional acti-
vation of Id1 gene. J Biol Chem 277(5):3176–3185.
Lu Y, Lotan R. 1999. Transcriptional regulation
by butyrate of mouse galectin-1 gene in embryo-
nal carcinoma cells. Biochim Biophys Acta
1444(1):85–91.
Marks PA, Miller T, Richon VM. 2003. Histone
deacetylases. Curr Opin Pharmacol 3(4):344–351.
McBurney MW. 1993. P19 embryonal carcinoma
cells. Int J Dev Biol 37(1):135–140.
McMahon JA, Takada S, Zimmerman LB, Fan CM,
Harland RM, McMahon AP. 1998. Noggin-medi-
ated antagonism of BMP signaling is required for
growth and patterning of the neural tube and
somite. Genes Dev 12(10):1438–1452.
Mirkes PE. 2002. 2001 Warkany lecture: to die or not to
die, the role of apoptosis in normal and abnormal
mammalian development. Teratology 65(5):228–239.
Miyashita T, Yamamoto H, Nishimune Y, Nozaki M,
Morita T, Matsushiro A. 1994. Activation of the
mouse cytokeratin A (endo A) gene in terato-
carcinoma F9 cells by the histone deacetylase
inhibitor Trichostatin A. FEBS Lett 353(2):225–229.
Miyazono K, Miyazawa K. 2002. Id: a target of BMP
signaling. Sci STKE 2002(151):PE40.
Moiseeva EP, Williams B, Goodall AH, Samani NJ.
2003. Galectin-1 interacts with beta-1 subunit of
integrin. Biochem Biophys Res Commun
310(3):1010–1016.
Na L, Wartenberg M, Nau H, Hescheler J, Sauer H.
2003. Anticonvulsant valproic acid inhibits car-
diomyocyte differentiation of embryonic stem
cells by increasing intracellular levels of reactive
oxygen species. Birth Defects Res Part A Clin
Mol Teratol 67(3):174–180.
Nagai T, Aruga J, Minowa O, Sugimoto T, Ohno Y,
Noda T, et al. 2000. Zic2 regulates the kinetics
of neurulation. Proc Natl Acad Sci USA
97(4):1618–1623.
Nagai T, Aruga J, Takada S, Gunther T, Sporle R,
Schughart K, et al. 1997. The expression of the
mouse Zic1, Zic2, and Zic3 gene suggests an
essential role for Zic genes in body pattern for-
mation. Dev Biol 182(2):299–313.
Nau H, Hauck RS, Ehlers K. 1991. Valproic acid-
induced neural tube defects in mouse and
human: aspects of chirality, alternative drug
development, pharmacokinetics and possible
mechanisms. Pharmacol Toxicol 69(5):310–321.
Nau H, Löscher W. 1986. Pharmacologic evaluation
of various metabolites and analogs of valproic
acid: teratogenic potencies in mice. Fundam Appl
Toxicol 6(4):669–676.
Nuwaysir EF, Bittner M, Trent J, Barrett JC, Afshari
CA. 1999. Microarrays and toxicology: the advent
of toxicogenomics. Mol Carcinog 24(3):153–159.
Oberemm A, Kirschbaum F. 1992. Valproic acid
induced abnormal development of the central
nervous system of three species of amphibians:
implications for neural tube defects and alterna-
tive experimental systems. Teratog Carcinog
Mutagen 12(6):251–262.
Ogra Y, Suzuki K, Gong P, Otsuka F, Koizumi S. 2001.
Negative regulatory role of Sp1 in metal respon-
sive element-mediated transcriptional activation.
J Biol Chem 276(19):16534–16539.
Paules R. 2003. Phenotypic anchoring: linking cause and
effect. Environ Health Perspect 111(6):A338–339.
Perillo NL, Marcus ME, Baum LG. 1998. Galectins:
versatile modulators of cell adhesion, cell prolif-
eration, and cell death. J Mol Med 76(6):402–412.
Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA,
Klein PS. 2001. Histone deacetylase is a direct
target of valproic acid, a potent anticonvulsant,
mood stabilizer, and teratogen. J Biol Chem
276(39):36734–36741.
Ramalho-Santos M, Yoon S, Matsuzaki Y, Mulligan RC,
Melton DA. 2002. “Stemness”: transcriptional pro-
ﬁling of embryonic and adult stem cells. Science
298(5593):597–600.
Rodriguez-Garcia MI, Morgan RO, Fernandez MR,
Bances P, Fernandez MP. 1999. Mouse annexin V
genomic organization includes an endogenous
retrovirus. Biochem J 337(pt 1):125–131.
Seaton BA, Dedman JR. 1998. Annexins. Biometals
11(4):399–404.
Shapland C, Hsuan JJ, Totty NF, Lawson D. 1993.
Puriﬁcation and properties of transgelin: a trans-
formation and shape change sensitive actin-
gelling protein. J Cell Biol 121(5):1065–1073.
Smith JL, Schoenwolf GC. 1997. Neurulation: coming
to closure. Trends Neurosci 20(11):510–517.
Smith L, Greenfield A. 2003. DNA microarrays and
development. Hum Mol Genet 12(spec no 1):R1–R8.
Suske G. 1999. The Sp-family of transcription factors.
Gene 238(2):291–300.
Svensson K, Mattsson R, James TC, Wentzel P,
Pilartz M, MacLaughlin J, et al. 1998. The pater-
nal allele of the H19 gene is progressively
silenced during early mouse development: the
acetylation status of histones may be involved in
the generation of variegated expression patterns.
Development 125(1):61–69.
Tanaka TS, Jaradat SA, Lim MK, Kargul GJ, Wang X,
Grahovac MJ, et al. 2000. Genome-wide expres-
sion profiling of mid-gestation placenta and
embryo using a 15,000 mouse developmental
cDNA microarray. Proc Natl Acad Sci USA
97(16):9127–9132.
Walmod PS, Skladchikova G, Kawa A, Berezin V,
Bock E. 1999. Antiepileptic teratogen valproic
acid (VPA) modulates organisation and dynamics
of the actin cytoskeleton. Cell Motil Cytoskeleton
42(3):241–255.
Wang Y, Dooher JE, Koedood Zhao M, Gilmore TD.
1999. Characterization of mouse Trip6: a putative
intracellular signaling protein. Gene 234(2):403–409.
Wegner C, Drews E, Nau H. 1990. Zinc concentra-
tions in mouse embryo and maternal plasma.
Effect of valproic acid and nonteratogenic
metabolite. Biol Trace Elem Res 25(3):211–217.
Werling U, Siehler S, Litfin M, Nau H, Gottlicher M.
2001. Induction of differentiation in F9 cells and
activation of peroxisome proliferator-activated
receptor delta by valproic acid and its teratogenic
derivatives. Mol Pharmacol 59(5):1269–1276.
Whitsel AI, Johnson CB, Forehand CJ. 2002. An
in ovo chicken model to study the systemic and
localized teratogenic effects of valproic acid.
Teratology 66(4):153–163.
Wlodarczyk BC, Craig JC, Bennett GD, Calvin JA,
Finnell RH. 1996. Valproic acid-induced changes
in gene expression during neurulation in a mouse
model. Teratology 54(6):284–297.
Xu W, Baribault H, Adamson ED. 1998. Vinculin
knockout results in heart and brain defects dur-
ing embryonic development. Development
125(2):327–337.
Yang WM, Inouye C, Zeng Y, Bearss D, Seto E. 1996.
Transcriptional repression by YY1 is mediated by
interaction with a mammalian homolog of the
yeast global regulator RPD3. Proc Natl Acad Sci
USA 93(23):12845–12850.
Yang YH, Dudoit S, Luu P, Lin DM, Peng V, Ngai J, et al.
2002. Normalization for cDNA microarray data: a
robust composite method addressing single and
multiple slide systematic variation. Nucleic Acids
Res 30(4):e15 [http://nar.oupjournals.org/cgi/
content/full/30/4/e15].
Ybot-Gonzalez P, Copp AJ. 1999. Bending of the
neural plate during mouse spinal neurulation is
independent of actin microfilaments. Dev Dyn
215(3):273–283.
Young MB, DiSilvestro MR, Sendera TJ, Freund J,
Kriete A, Magnuson SR. 2003. Analysis of gene
expression in carbon tetrachloride-treated rat
livers using a novel bioarray technology.
Pharmacogenomics J 3(1):41–52.
Yuan PX, Huang LD, Jiang YM, Gutkind JS, Manji HK,
Chen G. 2001. The mood stabilizer valproic acid
activates mitogen-activated protein kinases
and promotes neurite growth. J Biol Chem
276(34):31674–31683.
Zimmerman AW. 1984. Hyperzincemia in anencephaly
and spina bifida: a clue to the pathogenesis of
neural tube defects? Neurology 34(4):443–450.
Toxicogenomics | Valproic acid teratogenicity
Environmental Health Perspectives • VOLUME 112 | NUMBER 12 | August 2004 1235